LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 7, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Fly-E Group, Inc. ("Fly-E†or the "Company†) (NASDAQ: FLYE) securities between July 15, 2025 and August 14, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO LOST MONEY ON FLY-E (FLYE), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAW. ...

NEW YORK--(BUSINESS WIRE)---- $BYND #BFA--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Beyond Meat, Inc. (BYND) for securities fraud. ...

诉讼核心信息 - 律师事务所Levi & Korsinsky于2025年11月4日宣布，代表MoonLake Immunotherapeutics投资者提起集体诉讼证券诉讼 [1] - 诉讼针对纳斯达克上市公司MoonLake，股票代码为MLTX [1] - 诉讼涵盖的期间为2024年3月10日至2025年9月29日 [1] - 投资者申请担任首席原告的截止日期为2025年12月15日 [3] 诉讼指控详情 - 指控公司管理层在期间内作出虚假陈述和/或隐瞒信息 [2] - 具体指控包括：公司主要候选药物SLK与BIMZELX具有相同的分子靶点，即炎症细胞因子IL-17A和IL-17F [2] - 指控称SLK的纳米抗体结构并未比BIMZELX的传统单克隆结构带来更优的临床效益 [2] - 指控称SLK纳米抗体结构所宣称的增强组织渗透性并未转化为临床疗效 [2] - 基于以上指控，认为公司关于SLK优于单克隆抗体的积极陈述缺乏合理依据 [2]

Accessibility StatementSkip Navigation SOURCE Levi & Korsinsky, LLP 21% CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission-form?prid=175228&wire=4 SVRA investors may also contact Joseph E. Levi, Esq. via email at [email protected] o ...

Accessibility StatementSkip Navigation SAN DIEGO, Nov. 4, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of CarMax, Inc. (NYSE: KMX) publicly traded securities between June 20, 2025 and September 24, 2025, inclusive (the "Class Period"), have until January 2, 2026 to seek appointment as lead plaintiff of the CarMax class action lawsuit. Captioned Cap v. CarMax, Inc., No. 25-cv-03602 (D. Md.), the CarMax class action lawsuit charges CarMax and certain of CarMax' ...

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Synopsys, Inc. (NASDAQ: SNPS) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Synopsys, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/synopsys-inc. Investors have ...

诉讼背景 - 律师事务所Bleichmar Fonti & Auld LLP宣布，已对德康医疗及其部分高级管理人员提起集体诉讼，指控其涉嫌证券欺诈[1] - 诉讼依据为《1934年证券交易法》第10(b)条和第20(a)条，案件由美国纽约南区联邦地区法院审理，案号为Prime v DexCom Inc et al No 1:25-cv-08912[2] - 投资者申请担任首席原告的截止日期为2025年12月26日[2] 指控核心 - 公司被指控对其核心产品G6和G7连续血糖监测系统进行了未经授权的设计变更[4] - 这些变更降低了设备的准确性，使客户面临潜在的生命健康风险[4] - 指控称公司为了控制成本而忽视安全问题[4] - 在相关期间，公司曾宣传G7是市场上“最准确的CGM”，并称其改进“使之更好”、“丰富了客户体验”[3] 股价影响事件 - 2025年3月7日，公司披露收到FDA关于制造和质量控制问题的警告信，导致股价下跌7.12美元，跌幅超过9%[5] - 2025年3月25日，FDA公开警告信，揭示公司未经批准修改G6和G7，股价在两个交易日内进一步下跌3.19美元，跌幅超过4%[6] - 2025年9月18日，Hunterbrook发布报告《德康的致命缺陷》，引用FDA文件及医生、患者和员工陈述，称“G7用户曾住院并死亡”，且“公司文化将利润置于安全之上”，导致股价在两个交易日内下跌8.99美元，跌幅近12%[7]

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. ("Baxter International, Inc." or the "Company") (NYSE: BAX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Baxter International, Inc. investors who were adversely affected by alleged securities fraud between February 23, 2022 and July 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https: ...

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of aTyr investors who were adversely affected by alleged securities fraud between January 16, 2025 and September 12, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/atyr-pharma-inc-lawsuit-subm ...

诉讼概况 - Levi & Korsinsky律师事务所通知MoonLake Immunotherapeutics投资者一项集体诉讼证券诉讼 [1] - 诉讼旨在为在2024年3月10日至2025年9月29日期间因涉嫌证券欺诈而遭受损失的投资者挽回损失 [1] - 投资者需在2025年12月15日前请求法院指定其为首席原告 [3] 指控内容 - 指控称被告作出虚假陈述和/或隐瞒了以下事实：公司唯一的候选药物SLK与BIMZELX具有相同的分子靶点（炎症细胞因子IL-17A和IL-17F） [2] - 指控称SLK独特的纳米抗体结构不会比BIMZELX的传统单克隆结构带来更优越的临床益处 [2] - 指控称SLK纳米抗体结构所声称的增强组织渗透性不会转化为临床疗效 [2] - 基于上述情况，指控称被告对其关于SLK优于单克隆抗体的正面陈述缺乏合理依据 [2]